Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
304 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07015489 | Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer | completed | Phase 2 | 44 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07005401 | Factors Determine the Feasibility and Surgical Margin Quality of Sublobar Resection for Non-small Cell Lung Cancer? | completed | — | 1,064 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER |
| 1 |
| Jun 5, 2025 |
| clinicaltrials |
| NCT06988956 | Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 95 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06953739 | A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. | not yet recruiting | Phase 3 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT06926088 | Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer(CAMELIA) | active not recruiting | — | 500 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06779318 | Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis | not yet recruiting | Phase 4 | 464 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06908902 | Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors | recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | recruiting | Phase 2 | 148 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04866836 | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors | terminated | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06735287 | A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer | recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06208462 | Neoadjuvant Therapy of HAIC(GEMOX) Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | recruiting | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06853769 | Neoadjuvant Therapy for Locally Advanced Rectal Cancer(LARC-nCR01) | active not recruiting | Early Phase 1 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06837389 | Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors | not yet recruiting | Early Phase 1 | 18 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06838520 | Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer | not yet recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06835179 | SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer. | not yet recruiting | Phase 2 | 28 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 19, 2025 | clinicaltrials |
| NCT06830083 | Hypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based Reconstruction(HFIBR) | recruiting | N/A | 840 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06685289 | Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk | recruiting | Phase 2 | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06108596 | Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail(PICS) | completed | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06607276 | Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE(ACHIEVE) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06770296 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study | recruiting | Phase 1 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06766019 | Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 47 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06762782 | Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery | recruiting | Phase 2 | 276 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | recruiting | Phase 3 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05939830 | Omission of ALND in Breast Cancer Patients With Axillary pCR | recruiting | N/A | 92 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05974449 | Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients | recruiting | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06706726 | To Evaluate the Effectiveness and Safety of Single-port Robotic-assisted Subcutaneous Gland Resection Combined With Immediate Breast Reconstruction in Breast Cancer | not yet recruiting | N/A | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Nov 29, 2024 | clinicaltrials |
| NCT06698692 | Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma(COSELA) | recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06699498 | Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06696742 | PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma | recruiting | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05887661 | Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy | recruiting | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06674200 | A Retrospective Study Comparing the Incidence of Parastomal Hernia After Mesenteric Molding Suturing and Non-molding Suturing in Colostomy Surgery(COMPARISON) | completed | N/A | 11,243 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06656624 | Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) | recruiting | Phase 2 | 190 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04482803 | Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for CN+ Breast Cancer | completed | N/A | 159 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05508126 | Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer | recruiting | — | 222 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05935150 | Omission of SLNB in CN0 Early Breast Cancer | recruiting | N/A | 311 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06636747 | High Resolution Diffusion Weighted Imaging in Prostate | recruiting | — | 500 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06640153 | MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma | active not recruiting | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06613399 | Multi-Technology Integrated Total Mesorectal Excision Versus Conventional Total Mesorectal Excision for the Treatment of Middle and Distal Rectal Cancer. | not yet recruiting | N/A | 324 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06607250 | Bp-MRI Based Multi-planar VI-RADS | completed | — | 95 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06594432 | Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06564298 | A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis | unknown | Phase 2 | 39 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 28, 2024 | clinicaltrials |
| NCT06572501 | Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position | recruiting | N/A | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06569459 | Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06565923 | Study on the Staging and Prognosis Model of Bladder Cancer(2024-SR-386) | unknown | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06563869 | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06561646 | To Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer | not yet recruiting | N/A | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06524219 | Comparison of Nerve-sparing Techniques in Radical Prostatectomy for Oncological Outcome and Functional Recovery. | not yet recruiting | — | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 19, 2024 | clinicaltrials |
| NCT06555471 | A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06479460 | Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients | unknown | — | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06516978 | A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | not yet recruiting | Phase 2 | 528 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 24, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials